Structure-activity relationship studies:: M2 and CCR5 receptor antagonists

被引:5
|
作者
Boyle, CD [1 ]
Palani, A [1 ]
机构
[1] Schering Plough Res Inst, Kenilworth, NJ 07033 USA
关键词
D O I
10.2174/1568026033452032
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A wide range of neurotransmitters, polypeptides and inflammatory mediators transduce their signals into the interior of cell by specific interactions with cell-surface receptors that are coupled to G-protein. The most familiar G-protein-coupled receptors are muscarinic receptors, adrenergic receptors, dopaminergic receptors and opioid receptors. A single polypeptide chain of 400-500 residues forms most of these receptors. There are seven hydrophobic regions in the receptor and they correspond to transmembrane alpha-helices, which are membrane spanning domains. This topology is highly conserved among various members of the family of G-protein coupled receptors. The amino-terminal extracellular domain contains potential N-linked glycosylation sites in most receptors. The carboxyl-terminal is involved in the coupling to G-proteins and contains a cysteine site and phosphorylation site (Thr, Ser) and both are involved in receptor desensitization. In this section of the review we will discuss the development of potent, selective, low molecular weight antagonists of two G-protein coupled receptors (M-2 muscarinic receptor and CCR5 chemokine receptor) and their potential therapeutic utilities. The initial leads in both antagonist programs came from in house screening of our sample collections. As expected, most of the initial leads for both programs shared a similar pharmacophore and because of this showed strong affinity to many if not few a other G-protein coupled receptors. The initial significant challenge in both programs in terms of structure-activity studies was not only to optimize the structures for potency but also selectivity versus other subtype receptors. In the M-2 antagonist program the selectivity versus M-1 and other subtypes was a major challenge. Similarly in the CCR5 antagonist program the selectivity versus M-2 was a significant issue to overcome. In this review we will discuss in detail the structure activity relationships that resulted in potent and selective antagonists.
引用
收藏
页码:1155 / 1169
页数:15
相关论文
共 50 条
  • [1] Three-dimensional quantitative structure-activity relationship analyses of piperidine-based CCR5 receptor antagonists
    Song, MS
    Breneman, CM
    Sukumar, N
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (02) : 489 - 499
  • [2] Synthesis, binding affinity and structure-activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists
    Junker, Anna
    Kokornaczyk, Artur K.
    Zweemer, Annelien J. M.
    Frehland, Bastian
    Schepmann, Dirk
    Yamaguchi, Junichiro
    Itami, Kenichiro
    Faust, Andreas
    Hermann, Sven
    Wagner, Stefan
    Schaefers, Michael
    Koch, Michael
    Weiss, Christina
    Heitman, Laura H.
    Kopka, Klaus
    Wuensch, Bernhard
    [J]. ORGANIC & BIOMOLECULAR CHEMISTRY, 2015, 13 (08) : 2407 - 2422
  • [3] Isolation and structure of antagonists of chemokine receptor (CCR5)
    Jayasuriya, H
    Herath, KB
    Ondeyka, JG
    Polishook, JD
    Bills, GF
    Dombrowski, AW
    Springer, MS
    Siciliano, S
    Malkowitz, L
    Sanchez, M
    Guan, ZQ
    Tiwari, S
    Stevenson, DW
    Borris, RP
    Singh, SB
    [J]. JOURNAL OF NATURAL PRODUCTS, 2004, 67 (06): : 1036 - 1038
  • [4] Design, synthesis, and structure-activity relationship of novel CCR2 antagonists
    Kothandaraman, Shankaran
    Donnely, Karla L.
    Butora, Gabor
    Jiao, Richard
    Pasternak, Alexander
    Morriello, Gregori J.
    Goble, Stephen D.
    Zhou, Changyou
    Mills, Sander G.
    MacCoss, Malcolm
    Vicario, Pasquale P.
    Ayala, Julia M.
    DeMartino, Julie A.
    Struthers, Mary
    Cascieri, Margaret A.
    Yang, Lihu
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (06) : 1830 - 1834
  • [5] Quantitative structure activity relationship (QSAR) studies on sulphide analogues as potent M2 muscarinic receptor antagonists
    Srivastava, AK
    Khan, AA
    Tripathi, A
    Archana
    [J]. JOURNAL OF THE INDIAN CHEMICAL SOCIETY, 2005, 82 (09) : 850 - 852
  • [6] Structure-activity relationship studies on 2-heteroaryl-4-arylimidazoles NPY5 receptor antagonists
    Elliott, RL
    Oliver, RM
    LaFlamme, JA
    Gillaspy, ML
    Hammond, M
    Hank, RF
    Maurer, TS
    Baker, DL
    DaSilva-Jardine, PA
    Stevenson, RW
    Mack, CM
    Cassella, JV
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (20) : 3593 - 3596
  • [7] Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 1: Tuning the N-substituents
    Ben, Li
    Jones, Eric Dale
    Zhou, Enkun
    Li, Chen
    Baylis, Dean Cameron
    Yu, Shanghai
    Wang, Miao
    He, Xing
    Coates, Jonathan Alan Victor
    Rhodes, David Ian
    Pei, Gang
    Deadman, John Joseph
    Xie, Xin
    Ma, Dawei
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (14) : 4012 - 4014
  • [8] Small Molecule Antagonists of the Chemokine Receptor CCR5
    Lemoine, Remy C.
    Wanner, Jutta
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2010, 10 (13) : 1299 - 1338
  • [9] Design, synthesis and structure-activity relationship studies of novel 4,4-disubstituted piperidine based CCR5 antagonists as anti-HIV-1 agents
    Peckham, J
    Anderson, D
    Aquino, C
    Bifulco, N
    Boone, L
    Chong, P
    Duan, M
    Ferris, R
    Kazmierski, W
    Kenakin, T
    Lang, D
    McLean, E
    Svolto, A
    Wheelan, P
    Youngman, M
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2540 - U2540
  • [10] Effect of CCR5 receptor antagonists on endocytosis of the human CCR5 receptor in CHO-K1 cells
    Longden, J.
    Cooke, E-L
    Hill, S. J.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 (07) : 1513 - 1527